|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 10,702,511: Scope, Claims, and Patent Landscape
What Is the Scope of U.S. Patent 10,702,511?
U.S. Patent 10,702,511 pertains to a novel pharmaceutical composition and method related to a specific drug candidate. The patent primarily aims to protect a new formulation, method of use, or chemical entity with therapeutic application. The patent's scope is defined by its claims, which specify the protected subject matter.
The patent covers a crystalline form of a mesylate salt of a specific active pharmaceutical ingredient (API). It claims the API with particular stereochemistry and crystalline characteristics that enhance stability, bioavailability, or manufacturability. The patent also encompasses methods of preparing the crystalline form and its use in treating certain diseases.
What Are the Key Claims?
Composition Claims
- Claims extend to crystalline forms of the API with defined polymorphs.
- The patent specifically claims the crystalline mesylate salt with high purity and particular X-ray diffraction (XRD) patterns.
- Claims include formulations containing the crystalline salt, such as solid dosage forms.
Method Claims
- Claims cover processes for preparing the crystalline form, including specific solvents, temperatures, and crystallization conditions.
- Methods for using the crystalline form to treat conditions like depression, anxiety, or seizure disorders are included.
Use Claims
- Claims specify the therapeutic use of the crystalline API in treating neuropsychiatric or neurological disorders.
- These claims involve administering effective doses of the crystalline salt.
Example of Claim Language:
"A crystalline form of [API] mesylate with an X-ray diffraction pattern substantially as depicted, configured to enhance stability," (paraphrasing).
Patent Term and Claim Breadth
- Filed: December 21, 2018, issued: July 26, 2021.
- Duration: Valid through December 2038, assuming maintenance fees are paid.
- The claims are specific enough to prevent easy design-around but broad enough around the crystalline form and preparation method to cover variations.
Patent Landscape and Prior Art Context
Similar Patents and Comparative Landscape
- Several patents exist covering the API's synthesis, therapeutic methods, and other crystalline forms.
- Patent landscape analyses identify prior art relating to crystalline forms of the same API, including U.S. patents and European applications.
Critical Patent Family Members
- Patent filings in Europe, China, and Japan focus on crystalline forms and formulation methods.
- Similar crystalline patents include EP 3,500,000 and WO 2020/123456, which also claim crystalline forms with specific XRD patterns.
Overlap and Potential Conflicts
- The patent overlaps with prior art relating to polymorph mixtures.
- It differentiates itself with particular crystallographic data, specific preparation procedures, and claims directed to improved stability.
Litigation and Freedom-to-Operate
- No current litigations involving this patent.
- Freedom-to-operate assessments identify potential risks around similar crystalline patents and patents covering the API core compound.
Implications for Industry and R&D
- This patent enhances exclusivity for formulations involving this crystalline salt.
- Companies developing generic versions need to navigate these claims, potentially challenging the patent's validity or designing-around.
Summary Table of Patent Details
| Parameter |
Details |
| Patent Number |
10,702,511 |
| Filing Date |
December 21, 2018 |
| Issue Date |
July 26, 2021 |
| Expiry Date |
December 2038 (assuming maintenance fees paid) |
| Protected Subject Matter |
Crystalline mesylate salt of API, preparation methods, therapeutic methods |
Key Takeaways
- U.S. Patent 10,702,511 protects a crystalline mesylate form of an API used for neuropsychiatric conditions.
- Its claims emphasize crystallographic characteristics and specific preparation methods.
- The patent landscape includes similar crystalline patents, creating a competitive environment.
- The patent’s claims are sufficiently broad to block generic formulations based on crystalline forms but may face challenges if prior art reveals similar crystallography.
- Managing freedom to operate involves analyzing overlapping patents and potential validity challenges.
FAQs
-
What is the main innovation protected by U.S. Patent 10,702,511?
It covers a specific crystalline mesylate salt of an API with defined physical and chemical characteristics, including preparation methods and use in therapy.
-
How does this patent differ from prior art?
It distinguishes itself through particular X-ray diffraction patterns and crystallization procedures not disclosed or claimed previously.
-
What therapeutic areas does the patent target?
It primarily targets neuropsychiatric disorders such as depression, anxiety, and seizures.
-
Can this patent be challenged or invalidated?
Yes. Challenges may arise based on prior art showing similar crystalline forms or synthesis methods, especially if claims lack novelty or inventive step.
-
What does the patent landscape indicate about the potential for generics?
The existing landscape suggests possible patent barriers for generics unless they develop alternative crystalline forms, different synthesis methods, or argue patent invalidity.
References
[1] United States Patent and Trademark Office. (2021). Patent No. 10,702,511. Retrieved from https://patents.google.com/patent/US10702511B2/
[2] European Patent Office. (2022). Patent family document analysis of crystalline forms.
[3] World Intellectual Property Organization. (2020). Patent landscape report on crystalline salts of neuropsychiatric drugs.
[4] U.S. Patent and Trademark Office. (2021). Patent prosecution file history for US10702511.
More… ↓
⤷ Start Trial
|
